Multisystemic inflammatory syndrome in adults is a hyperinflammatory condition following
(within 4–12 weeks) SARS‐CoV‐2 infection. Here, the dysregulation of the immune system …

Aim To comprehensively review the literature on multisystem inflammatory syndrome in
children (MIS‐C). Methods Narrative review of relevant studies published between April …

Background The emergence of paediatric inflammatory multisystem syndrome temporally
associated with SARS-CoV-2 (PIMS-TS) led to the widespread use of anti-inflammatory …

Multisystem inflammatory syndrome in children (MIS‐C) is a rare, but severe complication of
coronavirus disease 2019 (COVID‐19). It develops approximately 4 weeks after severe …

Background: SARS-CoV-2 variations as well as immune protection after previous infections
and/or vaccination may have altered the incidence of multisystemic inflammatory syndrome …

Background Patients with multisystem inflammatory syndrome in children (MIS-C) and
Kawasaki disease (KD) have overlap** clinical features. We compared demographics …

Abstract Purpose of Review Multisystem inflammatory disease in children (MIS-C) is a novel
post-infectious phenomenon following coronavirus disease-19 (COVID-19). Herein, we …

This study aimed to investigate the characteristics of COVID-19-associated multisystem
inflammatory syndrome in children (MIS-C) and Kawasaki disease shock syndrome (KDSS) …

Background: PIMS-TS (pediatric inflammatory multisystem syndrome-temporally associated
with SARS-CoV-2) is a rare but serious condition in children following SARS-CoV-2 …

Background The treatment of children with multisystem inflammatory syndrome in children
(MIS-C) related to SARS-CoV-2 infection involves immunomodulatory therapies such as …